Kosuke Okuwaki

Kitasato University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (27)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background Residual or recurrent esophageal squamous cell carcinoma (ESCC) after definitive chemoradiotherapy (CRT) is a therapeutic challenge. Salvage surgery is invasive, and endoscopic resection is limited by radiation-induced fibrosis. Argon plasma coagulation (APC) and photodynamic therapy (PDT) are less invasive salvage options, however their role in depth-oriented organ-preserving strategies remains unclear. Methods We analyzed 52 consecutive patients with residual or recurrent ycT1–2 ESCC who underwent CRT. APC is indicated for ycT1a lesions, and PDT is indicated for ycT1b–T2 lesions, with flexibility. We evaluated the survival rates, adverse events, and predictors of local failure. Results Thirteen patients underwent APC, and 39 underwent PDT. The overall local complete response rate was 78.8% (92.3% APC and 74.3% PDT). During a median follow-up of 24.7 months (range, 1.9–110.5 months), the 2-year overall survival, progression-free survival, disease-specific survival, and esophagectomy-free survival rates were 82.8%, 44.0%, 86.7%, and 75.9%, respectively. Adverse events occurred in 30.8% of APC patients and 41.0% of PDT patients, all of which were manageable without treatment-related mortality. Multivariate analysis identified ycT2 stage (hazard ratio [HR]: 9.61, 95% confidence interval [CI]: 1.04–88.55, P = .04) and tumor location in the upper thoracic esophagus (HR 3.48, 95% CI 1.02–11.85; P = .04) as independent predictors of local failure. Conclusions A salvage endoscopic strategy applying APC for ycT1a and PDT for ycT1b–T2, with flexibility based on tumor depth, is feasible, safe, and effective. Tailoring treatment to invasion depth may optimize organ preservation and local control in residual or recurrent ESCC after CRT.

Year:

2026

Objectives Balloon enteroscopy‐assisted endoscopic retrograde cholangiopancreatography (BE‐assisted ERCP) is performed for hepaticojejunostomy anastomotic stricture (HJAS) after biliary‐enteric anastomosis. Although endoscopic balloon dilation (EBD) and plastic stent (PS) placement are commonly performed, they result in high recurrence rates. Studies have demonstrated the efficacy of fully covered self‐expanding metal stents (FCSEMS) in HJAS management; however, none have systematically evaluated the outcomes of 6‐month placement. Therefore, this retrospective study aimed to evaluate the efficacy and safety of a 6‐month FCSEMS placement for benign refractory or recurrent HJAS. Methods We evaluated patients who underwent initial treatment with EBD alone or EBD plus PS placement via BE‐assisted ERCP between April 2015 and March 2024. Among them, patients with refractory or recurrent HJAS received 6‐month FCSEMS placements. The study outcomes were HJAS resolution, adverse events (AEs), and recurrence rates. Results Among 92 patients who underwent initial EBD alone or EBD with PS placement, the HJAS resolution rate was 90.2%. The median follow‐up period after the initial treatment was 16.1 months, with recurrence observed in 48.2% of patients. Among the 34 patients with refractory or recurrent HJAS, FCSEMS placement achieved a resolution rate of 97.1% in a median of 182 days. AEs occurred in 14.7% of patients (moderate, n = 3; mild, n = 2) following FCSEMS placement. During a median follow‐up of 30.9 months, no recurrence was observed after HJAS resolution using FCSEMS. Conclusions The 6‐month FCSEMS placement for refractory or recurrent HJAS showed high efficacy and safety, indicating its potential as a preferred treatment option.

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

光広 木田

Professor

Kitasato University

JAPAN
View details

Masayoshi Tadehara

Kitasato University

JAPAN
View details

Yoji Takeuchi

Professor

Kindai University

JAPAN
View details

Hisashi Hidaka

Kitasato University School of Medicine

JAPAN
View details

Nobuyuki Nishizawa

Junior Associate Professor

Kitasato University

JAPAN
View details